Mechanisms of resistance to hormonal treatment in breast cancer

被引：12

作者：

Eroles, Pilar ^{[2
]}

Bosch, Ana ^{[2
]}

Bermejo, Begona ^{[1
]}

Lluch, Ana ^{[1
,2
]}

机构：

[1] Hosp Clin Univ Valencia, Serv Hematol & Oncol Med, ES-46010 Valencia, Spain

[2] Hosp Clin Univ Valencia, Fdn Invest, ES-46010 Valencia, Spain

来源：

CLINICAL & TRANSLATIONAL ONCOLOGY | 2010年 / 12卷 / 04期

关键词：

Breast cancer; Hormonal treatment; Resistance; CYPD2D6; TK inhibitors; AIB1; PAX2; ESTROGEN-RECEPTOR-ALPHA; ENDOCRINE-THERAPY RESISTANCE; NITRIC-OXIDE SYNTHASE; TAMOXIFEN RESISTANCE; PHASE-II; CYP2D6; GENOTYPE; CROSS-TALK; N-COR; EXPRESSION; ACTIVATION;

D O I：

10.1007/s12094-010-0500-1

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Endocrine therapy is a cornerstone in hormone-dependent breast cancer treatment. Despite the effectiveness of this type of treatment, a significant percentage of tumours develop resistance, and hence, patients relapse. This raises the question of which mechanisms are activated by hormone-dependent tumours to become resistant to antihormonal therapy. The aim of this review is to summarise the current knowledge on structure and mechanisms of action of oestrogen receptors and the possible mechanisms of resistance known to date, focusing on the existing crosstalk between oestrogen receptor and growth factor receptor pathways as well as the influence of drug metabolism in its effectiveness. Finally, the clinical evidence of hormonal therapy resistance and the future directions for optimising breast cancer treatment is also discussed.

引用

页码：246 / 252

页数：7

共 63 条

[21] Estrogen induces the Akt-dependent activation of endothelial nitric-oxide synthase in vascular endothelial cells [J].

Hisamoto, K ;

Ohmichi, M ;

Kurachi, H ;

Hayakawa, J ;

Kanda, Y ;

Nishio, Y ;

Adachi, K ;

Tasaka, K ;

Miyoshi, E ;

Fujiwara, N ;

Taniguchi, N ;

Murata, Y .

JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (05) :3459-3467

[22] CYP2D6 and tamoxifen: DNA matters in breast cancer [J].

Hoskins, Janelle M. ;

Carey, Lisa A. ;

Mcleod, Howard L. .

NATURE REVIEWS CANCER, 2009, 9 (08) :576-586

[23] Regulation of ERBB2 by oestrogen receptor-PAX2 determines response to tamoxifen [J].

Hurtado, Antoni ;

Holmes, Kelly A. ;

Geistlinger, Timothy R. ;

Hutcheson, Iain R. ;

Nicholson, Robert I. ;

Brown, Myles ;

Jiang, Jie ;

Howat, William J. ;

Ali, Simak ;

Carroll, Jason S. .

NATURE, 2008, 456 (7222) :663-U93

[24] The partial agonist activity of antagonist-occupied steroid receptors is controlled by a novel hinge domain-binding coactivator L7/SPA and the corepressors N-CoR or SMRT [J].

Jackson, TA ;

Richer, JK ;

Bain, DL ;

Takimoto, GS ;

Tung, L ;

Horwitz, KB .

MOLECULAR ENDOCRINOLOGY, 1997, 11 (06) :693-705

[25]

JENSEN EV, 1962, RECENT PROG HORM RES, V18, P387

[26] CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment [J].

Jin, Y ;

Desta, Z ;

Stearns, V ;

Ward, B ;

Ho, H ;

Lee, KH ;

Skaar, T ;

Storniolo, AM ;

Li, L ;

Araba, A ;

Blanchard, R ;

Nguyen, A ;

Ullmer, L ;

Hayden, J ;

Lemler, S ;

Weinshilboum, RM ;

Rae, JM ;

Hayes, DF ;

Flockhart, DA .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2005, 97 (01) :30-39

[27] Lapatinib Combined With Letrozole Versus Letrozole and Placebo As First-Line Therapy for Postmenopausal Hormone Receptor-Positive Metastatic Breast Cancer [J].

Johnston, Stephen ;

Pippen, John, Jr. ;

Pivot, Xavier ;

Lichinitser, Mikhail ;

Sadeghi, Saeed ;

Dieras, Veronique ;

Gomez, Henry Leonidas ;

Romieu, Gilles ;

Manikhas, Alexey ;

Kennedy, M. John ;

Press, Michael F. ;

Maltzman, Julie ;

Florance, Allison ;

O'Rourke, Lisa ;

Oliva, Cristina ;

Stein, Steven ;

Pegram, Mark .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (33) :5538-5546

[28] A phase II, randomized, blinded study of the farnesyltransferase inhibitor tipifarnib combined with letrozole in the treatment of advanced breast cancer after antiestrogen therapy [J].

Johnston, Stephen R. D. ;

Semiglazov, Vladimir F. ;

Manikhas, George M. ;

Spaeth, Dominique ;

Romieu, Gilles ;

Dodwell, David J. ;

Wardley, Andrew M. ;

Neven, Patrick ;

Bessems, Annick ;

Park, Youn C. ;

De Porre, Peter M. ;

Ruixo, Juan J. Perez ;

Howes, Angela J. .

BREAST CANCER RESEARCH AND TREATMENT, 2008, 110 (02) :327-335

[29] Trastuzumab Plus Anastrozole Versus Anastrozole Alone for the Treatment of Postmenopausal Women With Human Epidermal Growth Factor Receptor 2-Positive, Hormone Receptor-Positive Metastatic Breast Cancer: Results From the Randomized Phase III TAnDEM Study [J].

Kaufman, Bella ;

Mackey, John R. ;

Clemens, Michael R. ;

Bapsy, Poonamalle P. ;

Vaid, Ashok ;

Wardley, Andrew ;

Tjulandin, Sergei ;

Jahn, Michaela ;

Lehle, Michaela ;

Feyereislova, Andrea ;

Revil, Cedric ;

Jones, Alison .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (33) :5529-5537

[30] Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor β [J].

Kuiper, GGJM ;

Lemmen, JG ;

Carlsson, B ;

Corton, JC ;

Safe, SH ;

van der Saag, PT ;

van der Burg, P ;

Gustafsson, JÄ .

ENDOCRINOLOGY, 1998, 139 (10) :4252-4263

← 1 2 3 4 5 6 7 →